Dosing has now begun in a Phase 2 proof-of-concept trial for BTRX-140 in a subpopulation of patients with major depressive disorder.
The KOR neuropeptide system is an important mediator of the negative effects of stress-induced alterations on mood, emotional regulation and motivation. KOR antagonism is a novel therapeutic approach, which offers the potential to address key drivers of disability, such as depressed mood, anxiety, anhedonia and cognitive impairment.
These clinical symptoms commonly occur in multiple CNS disorders, but are not adequately addressed by currently available medications for many people seeking therapy.
The Phase 2 proof-of-concept trial is a double-blind, placebo-controlled, randomized trial designed to evaluate the efficacy, safety and tolerability of BTRX-140 in approximately 120 patients with major depressive disorder.
The primary endpoint of the trial is change in Hamilton Rating Scale for Depression (HAM-D) total score in the BTRX-140 treatment group compared to the placebo group following eight weeks of treatment.
BTRX-140 is a potent, selective KOR antagonist being investigated for the treatment of neurobehavioral disorders, including major depressive disorder.
Activation of the KOR system under conditions of stress and disease can contribute to symptoms associated with depressed mood, anhedonia, anxiety and cognitive impairment, which are key drivers of disability in numerous psychiatric and neurological disorders.
BTRX-140 is intended to reduce stress responses and restore dysregulated brain networks underlying these symptom domains, providing a novel therapeutic approach to treating neurobehavioral disorders. BTRX-140 was discovered as part of a research collaboration with The Scripps Research Institute.
BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system disorders.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference